Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

[1]  H. D. de Melker,et al.  Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections , 2022, Nature Communications.

[2]  E. Fernandes,et al.  Risk of BA.5 infection in individuals exposed to prior SARS-CoV-2 variants , 2022, medRxiv.

[3]  Rupal M Mody,et al.  Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection , 2022, bioRxiv.

[4]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[5]  D. Studdert,et al.  Protection against Omicron conferred by mRNA primary vaccine series, boosters, and prior infection , 2022, medRxiv.

[6]  N. Pearce,et al.  Vaccination plus previous infection: protection during the omicron wave in Brazil , 2022, The Lancet Infectious Diseases.

[7]  A. Sigal,et al.  Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity , 2022, medRxiv.

[8]  M. Brisson,et al.  Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination , 2022, medRxiv.

[9]  P. Maes,et al.  Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies , 2022, medRxiv.

[10]  J. L. Bernal,et al.  COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England , 2022, The Lancet Infectious Diseases.

[11]  D. Barouch,et al.  Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, The New England journal of medicine.

[12]  Gheyath K Nasrallah,et al.  Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.

[13]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[14]  Gheyath K Nasrallah,et al.  Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.

[15]  T. Pavlík,et al.  Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2 , 2022, medRxiv.

[16]  H. Ullum,et al.  Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection , 2022, medRxiv.

[17]  Khatib,et al.  Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants , 2022 .

[18]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[19]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[20]  C. Broder,et al.  Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection , 2021, bioRxiv.

[21]  P. Lescuyer,et al.  Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study , 2021, Clinical Infectious Diseases.

[22]  P. Klenerman,et al.  SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) , 2021, The Lancet.

[23]  J. Merckx,et al.  Identifiability and Estimation Under the Test-negative Design With Population Controls With the Goal of Identifying Risk and Preventive Factors for SARS-CoV-2 Infection. , 2020, Epidemiology.

[24]  B. Cao,et al.  Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity , 2020, Clinical Microbiology and Infection.